Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury.
Christopher M CirnigliaroMichael F La FountaineJ Scott ParrottSteven C KirshblumSusan J SauerSue A ShapsesIsa A McClureWilliam A BaumanPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)
In persons with SCI who initiated denosumab treatment during the subacute injury phase and maintained treatment for 1 year, the discontinuation of drug resulted in percent loss of mean BMD similar to that of the placebo group, with absolute mean BMD values at the knee regions at the 12-month follow-up visit significantly higher in the drug treatment than those in the placebo group. These data underscore the need to study continued administration of denosumab after subacute SCI to avoid marked demineralization in the sublesional skeleton upon discontinuation of this agent.